Compositions and methods for reducing methane emissions in ruminant populations
US-2024009291-A1 · Jan 11, 2024 · US
Controlled release pharmaceutical compositions of tapentadol
US9884022B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9884022-B2 |
| Application number | US-201113638239-A |
| Country | US |
| Kind code | B2 |
| Filing date | Feb 7, 2011 |
| Priority date | Apr 7, 2010 |
| Publication date | Feb 6, 2018 |
| Grant date | Feb 6, 2018 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
A once daily controlled release pharmaceutical compositions comprising tapentadol, wherein preferably the mean T max of tapentadol is reached after 10 hours of administration of the composition. The composition comprises tapentadol, such that it maintains serum concentration of tapentadol of at least about 20 ng/ml for at least about 17 hours after oral administration of the composition. According to one embodiment the controlled release pharmaceutical composition comprises tapentadol, which is gastroretentive.
First claim
Opening claim text (preview).
The invention claimed is: 1. A controlled release pharmaceutical composition comprising: an immediate release component comprises about 4% to about 12% of tapentadol a delayed release component comprises about 32% to about 84% of tapentadol, and a controlled release component comprises about 18% to about 65% of tapentadol by weight of total weight of tapentadol in the composition, wherein the composition is gastroretentive and maintains serum concentration of tapentadol of at least 20 ng/ml for at least 17 hours after once daily oral administration of the composition. 2. The controlled release pharmaceutical composition of claim 1 , wherein the composition is multilayered. 3. The controlled release pharmaceutical composition of claim 2 , wherein the composition is trilayered comprising first, second and third layer wherein the first layer comprises controlled release component, second layer comprises immediate release component and the third layer comprises delayed release component. 4. The controlled release pharmaceutical composition of claim 3 , wherein immediate release component, a controlled release component, and a delayed release component comprises tapentadol. 5. The controlled release pharmaceutical composition of the claim 1 , wherein the pharmaceutical composition maintains at least 10 ng/ml serum concentration of tapentadol for at least 14 hours after administration. 6. The controlled release pharmaceutical compositions of claim 1 further comprise one or more active ingredients. 7. The controlled release pharmaceutical compositions of claim 1 , wherein the composition is used for the treatment of pain.
Assignees
Inventors
Classifications
Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine {or methadone} · CPC title
Organic compounds, e.g. phospholipids, fats · CPC title
Centrally acting analgesics, e.g. opioids · CPC title
- A61K9/209Primary
containing drug in at least two layers or in the core and in at least one outer layer · CPC title
Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin (homeopathic globules A61K9/1623) · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9884022B2 cover?
- A once daily controlled release pharmaceutical compositions comprising tapentadol, wherein preferably the mean T max of tapentadol is reached after 10 hours of administration of the composition. The composition comprises tapentadol, such that it maintains serum concentration of tapentadol of at least about 20 ng/ml for at least about 17 hours after oral administration of the composition. Accor…
- Who is the assignee on this patent?
- Deshmukh Ashish Ashokrao, Bhutada Pravin Meghrajji, Chandran Sajeev, and 2 more
- What technology area does this patent fall under?
- Primary CPC classification A61K9/209. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Feb 06 2018 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).